# CORRESP — NovaBay Pharmaceuticals, Inc.  (NBY)  (CIK 0001389545)

> <strong>NovaBay Pharmaceuticals, Inc.  (NBY)  (CIK 0001389545) → SEC staff</strong> · filed 2025-11-25 · ticker NBY · SIC 2834

## What is this

A CORRESP letter is the company's written reply to the SEC during a filing review. Responses include accounting position arguments, restatement assessments, and clarifying disclosures. Released to EDGAR alongside the SEC's UPLOAD letters.

## Key facts

- **Accession number:** 0001437749-25-036356
- **Form:** CORRESP
- **Filer:** NovaBay Pharmaceuticals, Inc.  (NBY)  (CIK 0001389545)
- **CIK:** 0001389545
- **Ticker:** NBY
- **Filed:** 2025-11-25
- **SIC industry:** 2834
- **HQ:** Emeryville, CA

## Primary source

PDF letter: https://www.sec.gov/Archives/edgar/data/1389545/000143774925036356/filename1.htm

EDGAR review history for this filer: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1389545&type=UPLOAD&dateb=&owner=include&count=40

## Citation

> US Securities and Exchange Commission, EDGAR CORRESP comment letter, NovaBay Pharmaceuticals, Inc.  (NBY)  (CIK 0001389545) (CIK 0001389545), filed 2025-11-25, accession 0001437749-25-036356. Retrieved via MORVS 2026-11-06 from https://api.morvs.ai/comment-letter/0001437749-25-036356.

---

*[SEC comment letters dataset](/datasets/sec-comment-letters) · CC0 1.0*